[1]
|
Stryjewski, M.E. and Corey G.R. (2014) Methicillin-Resistant Staphylococcus: An Evolving Pathogen. Clinical Infectious Diseases, 58, S10-S19. http://dx.doi.org/10.1093/cid/cit613
|
[2]
|
Greenlee-Wacker, M., DeLeo, F.R. and Nauseef W.M. (in Press) How Methicillin-Resistant Staphylococcus aureus Evade Neutrophil Killing. Current Opinion in Hematology.
|
[3]
|
CDC. http://www.cdc.gov/drugresistance/threat-report-2013/pdf
|
[4]
|
Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B. and Fridkin, S. (2013) Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-1020. Infection Control Hospital Epidemiology, 34, 1-14. http://dx.doi.org/10.1086/668770
|
[5]
|
Clinical and Laboratory Standards Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement. CLSI Document M100-S23, Clinical and Laboratory Standards Institute, Wayne.
|
[6]
|
Cookson, B.D. (1998) The Emergence of Mupirocin Resistance: A Challenge to Infection Control and Antibiotic Prescribing Practice. Journal of antimicrobial Chemotherapy, 41, 11-18. http://dx.doi.org/10.1093/jac/41.1.11
|
[7]
|
Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C.K., Keohane, C., Denham, C.R. and Bates, D.W. (2013) Healthcare-Associated Infections: A Meta-Analysis of Costs and Financial Impact on the US Health Care System. JAMA Internal Medicine, 173, 2039-2046. http://dx.doi.org/10.1001/jamainternmed.2013.9763
|
[8]
|
Scott, R.D. (2009) The Direct Medical Costs of Healthcare-Associated Infections in US Hospitals and the Benefits of Prevention. http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf
|
[9]
|
Sader, H.S., Fey, P.D., Fish, D.N., Limaye, A.P., Pankey, G., Rahal, J., Rybak, M.J., Snydman, D.R., Steed, L.L., Waites, K. and Jones, R.N. (2009) Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine US Medical Centers from 2002 to 2006. Antimicrobial Agents and Chemotherapy, 53, 4127-4132. http://dx.doi.org/10.1128/AAC.00616-09
|
[10]
|
Jacob, J.T. and DiazGranados, C.A. (2013) High Vancomycin Minimum Inhibitory Concentration and Clinical Outcomes in Adults with Methicillin-Resistant Staphylococcus aureus Infections: A Meta-Analysis. International Journal of Infectious Diseases, 17, e93-e100.
|
[11]
|
Sakoulas, G., Moise-Broder, P.A., Schentag, J., Forrest, A., Moellering Jr., R.C. and Eliopoulos, G.M. (2004) Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of Clinical Microbiology, 42, 2398-2402. http://dx.doi.org/10.1128/JCM.42.6.2398-2402.2004
|
[12]
|
Brink, A.J. (2012) Does Resistance in Se-vere Infections Caused by Methicillin-Resistant Staphylococcus aureus Give You the “Creeps”? Current Opinion in Critical Care, 18, 451-459. http://dx.doi.org/10.1097/MCC.0b013e3283578968
|
[13]
|
Bland, C.M., Porr, W.H., Davis, K.A. and Mansell, K.B. (2010) Vancomycin MIC Susceptibility Testing of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison between Etest® and an Automated Testing Method. Southern Medical Journal, 103, 1124-1128. http://dx.doi.org/10.1097/SMJ.0b013e3181efb5b1
|
[14]
|
Arunava, K., Selvaraj, S., Sivaraman, U., Shailesh, K., Noyal, M.J. and Sreenivasan, S. (2013) Changing Trends in Resistance Pattern of Methicillin Resistant Staphylococcus aureus. Journal of Clinical and Diagnostic Research, 7, 1979-1982.
|
[15]
|
Richter, S.S., Diekema, D.J., Heilmann, K.P., Dohrn, C.L., Crispell, E.K., Riahi, F., McDanel, J.S., Satola, S.W. and Doern, G.V. (2014) Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States. Antimicrobial Agents and Chemotherapy, 58, 740-745. http://dx.doi.org/10.1128/AAC.01915-13
|
[16]
|
Lee, H., Lim, H., Bae, I.K., Yong, D., Jeong, S.H., Lee, K. and Chong, Y. (2013) Co-Existance of Mupirocin and Antiseptic Resistance in Methicillin-Resistant Staphylococcus aureus Isolates from Korea. Diagnostic Microbiology and Infectious Disease, 75, 308-312. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.025
|
[17]
|
Woodford, N., Afzal-Shah, M., Warner, M. and Livermore, D.M. (2008) In Vitro Activity of Retapamulin against Staphylococcus aureus Isolates Resistant to Fusidic Acid and Mupirocin. Journal of Antimicrobial Chemotherapy, 62, 766-768. http://dx.doi.org/10.1093/jac/dkn266
|
[18]
|
Patel, J.B., Gorwitz, R.J. and Jernigan, J.A. (2009) Mupirocin Resistance. Clinical Infectious Diseases, 49, 935-941. http://dx.doi.org/10.1086/605495
|
[19]
|
Schweizer, M.L. and Herwaldt, L.A. (2012) Surgical Site Infections and Their Prevention. Current Opinion in Infectious Disease, 25, 378-384. http://dx.doi.org/10.1097/QCO.0b013e32835532f7
|
[20]
|
van Rijen, M.M.L., Bonten, M., Wenzel, R.P. and Kluytmans, J.A.J.W. (2008) Intranasal Mupirocin for Reduction of Staphylococcus aureus Infections in Surgical Patients with Nasal Carriage: A Systematic Review. Journal of Antimicrobial Chemotherapy, 61, 254-261. http://dx.doi.org/10.1093/jac/dkm480
|
[21]
|
Robotham, J.V., Graves, N., Cookson, B.D., Barnett, A.G., Wilson, J.A., Edgeworth, J.D., Batra, R., Cuthbertson, B.H. and Cooper, B.S. (2011) Screening, Isolation, and Decolonization Strategies in the Control of Methicillin Resistant Staphylococcus aureus in Intensive Care Units: Cost Effectiveness Evaluation. British Medical Journal, 343, Article ID: d5694. http://dx.doi.org/10.1136/bmj.d5694
|
[22]
|
Courville, X.F., Tomek, I.M., Kirkland, K.B., Birhle, M., Kantor, S.R. and Finlayson, S.R.G. (2012) Cost-Effectiveness of Preoperative Nasal Mupirocin Treatment in Preventing Surgical Site Infection in Patients Undergoing Total Hip and Knee Arthroplasty: A Cost-Effectiveness Analysis. Infection Control and Hospital Epidemiology, 33, 152-159. http://dx.doi.org/10.1086/663704
|
[23]
|
Goldsack, J.C., DeRitter, C., Power, M., Spencer, A., Taylor, C.L., Kim, S.F., Kirk, R. and Drees, M. (2014) Clinical, Patient Experience and Cost Impacts of Performing Active Surveillance on Known Methicillin-Resistant Staphylococcus aureus Positive Patients Admitted to Medical-Surgical Units. American Journal of Infection Control, 42, 1039-1043. http://dx.doi.org/10.1016/j.ajic.2014.07.011
|
[24]
|
Huang, S.S., Septimus, E., Avery, T.R., Lee, G.M., Hickok, J., Weinstein, R.A., Moody, J., Hayden, M.K., Perlin, J.B., Platt, R. and Ray, G.T. (2014) Cost Savings of Universal Decolonization to Prevent Intensive Care Unit Infection: Implications of the REDUCE MRSA Trial. Infection Control Hospital Epidemiology, 35, S23-S31. http://dx.doi.org/10.1086/677819
|
[25]
|
Livermore, D.M. and Pearson, A. (2007) Antibiotic Resistance: Location, Location, Location. Clinical Microbiology and Infection, 13, 7-16. http://dx.doi.org/10.1111/j.1469-0691.2007.01724.x
|